Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia. - Wikidata - wikimedia - TriplyDB

Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia.

Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia.

http://www.wikidata.org/entity/Q52915313

about

Inhaled innate immune ligands to prevent pneumonia.Synthetic lipopeptide MALP-2 inhibits intracellular growth of Mycobacterium bovis BCG in alveolar macrophages-preliminary data.What is the clinical relevance of different lung compartments?Effects of the TLR2 agonists MALP-2 and Pam3Cys in isolated mouse lungs mCLCA3 modulates IL-17 and CXCL-1 induction and leukocyte recruitment in murine Staphylococcus aureus pneumonia.Murine CLCA5 is uniquely expressed in distinct niches of airway epithelial cells.Inducible innate resistance of lung epithelium to infection.Inhaled therapeutics for prevention and treatment of pneumonia Pulmonary immunostimulation with MALP-2 in influenza virus-infected mice increases survival after pneumococcal superinfection Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice.Mycoplasma fermentans MALP-2 induces heme oxygenase-1 expression via mitogen-activated protein kinases and Nrf2 pathways to modulate cyclooxygenase 2 expression in human monocytes.Innate immune recognition in infectious and noninfectious diseases of the lung.Heterotopic ossifications following implant surgery--epidemiology, therapeutical approaches and current concepts.Adjuvant immunotherapies as a novel approach to bacterial infections.TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease.Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs.MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock.A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.Reducing the impact of influenza-associated secondary pneumococcal infections.Miniaturized bronchoscopy enables unilateral investigation, application, and sampling in mice.Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia.Vasculotide reduces pulmonary hyperpermeability in experimental pneumococcal pneumonia.Spectrum of pathogen- and model-specific histopathologies in mouse models of acute pneumonia.

P2860

Q30398752-2D3EB046-B337-4983-8F14-3F159BAF0F89 Q33471549-F26796F8-AF62-4ABD-9F4D-0B4EDFE47F90 Q33492575-777F781F-19F6-4B38-A11A-EC7A6E3978C0 Q33761304-A074FE68-DD58-4331-AAE4-8E4387ED5864 Q33916302-66C19E4E-67CA-4844-AB0D-D8BD622F022A Q35050527-C4E9090D-628D-45C1-A29C-862AABD87C9E Q35754472-6381C861-F72A-472E-A285-F91F0268F1B0 Q35925366-47A26234-1932-4125-8D3E-D4AF4AEF6DEF Q36281381-F22945BC-35F3-42FA-8A87-EC44490E569F Q36845161-17E4C213-6781-4E1C-BE3D-3F1B5F5F554B Q36911318-BA9EC656-9C17-496F-83B9-0674CAE63685 Q37694915-3FB6E3D5-3B09-4CDF-9204-B09A75D87453 Q37829358-9DB00BE6-1C30-4759-A5E7-0918395E5E4C Q38096056-EF13B768-FB4A-4C50-9A90-3ACB70F34F2B Q38195597-4A50869F-2766-4627-97C6-F3407E58EC12 Q39173330-406A255D-D0FB-40A1-9B96-2FA65435457D Q40275846-57FE040B-3956-4FF9-91C5-804CBFFB6575 Q40462015-0091E09D-3D9E-45B9-8069-570C7645BB92 Q41128275-1A095260-6DE7-4357-B017-9F20966865F8 Q42210341-E4492A0E-0AD5-46AE-89D7-7489D1DC8222 Q42264677-527FB0D3-F8DA-40A7-95CB-58F63631D419 Q45154780-28061636-F6C6-44BD-934E-5B78BA8059E8 Q46258141-F3809D3A-F83C-4C9E-8F70-D51E647214B0

P2860

Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia.

http://www.wikidata.org/entity/Q52915313

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Immunostimulation with macroph ...... survival in murine pneumonia.

@en

Immunostimulation with macroph ...... survival in murine pneumonia.

@nl

type

label

Immunostimulation with macroph ...... survival in murine pneumonia.

@en

Immunostimulation with macroph ...... survival in murine pneumonia.

@nl

prefLabel

Immunostimulation with macroph ...... survival in murine pneumonia.

@en

Immunostimulation with macroph ...... survival in murine pneumonia.

@nl

P1433

Q52915313-48689DDA-CD81-485D-A943-30C1956EAECB

P1476

Q52915313-FA47592C-388C-4234-9D94-01052F03CF2D

P2093

Q52915313-01372557-3EC6-42CF-A9C4-FFE4C457A20B

Q52915313-08AB4064-9847-4B35-8B6E-AC9AEBAD948C

Q52915313-104659EF-D90F-4249-B653-374847145094

Q52915313-1F79F301-FFCC-4D97-89BD-3E09F49EC172

Q52915313-27829196-9162-4048-929A-7A2DA09ED70B

Q52915313-3DD764A3-1569-4BAE-B2CB-1E90125BC6F2

Q52915313-51560760-4FA8-4E07-ACF4-C19202AFD9AF

Q52915313-547D335C-4402-41A2-B978-EDB011A4E363

Q52915313-86C653AC-B027-4EAF-AFF7-BE8553B95FDB

Q52915313-8AD9BB44-6D3F-4BB3-8A86-249819A345BF

P2860

Q52915313-06C28A1E-DA4D-45AC-B8EE-9DD6D5028964

Q52915313-179D0515-B15F-4332-92F5-0CBD89F61DB4

Q52915313-20FC07C9-690B-4C72-BF55-C5440E49935A

Q52915313-3507F0D6-0A9C-473D-AE85-D47A993BD587

Q52915313-3697A2C3-28D6-49B1-8635-1805D637A058

Q52915313-393C2D49-39C1-4698-A946-3DE643484F31

Q52915313-4A2B8F8A-29DE-4BE0-A97D-981AD1837B59

Q52915313-5299ED2D-1B6D-4232-ABDB-A6713BACA4A7

Q52915313-53D833A6-EFD8-4611-AE85-D70DD111521A

Q52915313-55FD6969-DA3B-4488-B4A4-07AD66E44FD0

P304

Q52915313-EE691CF9-5657-4B7E-866F-694C367D93AE

P31

Q52915313-73A43D92-0A6C-4550-8155-D67CE50C6177

P356

Q52915313-66BAC517-DDA2-446B-9385-57515154DC94

P433

Q52915313-E0FED30D-615F-4C23-A79F-09409E9F09E7

P478

Q52915313-6B293097-29F6-4EE7-8C8B-8B34B8E6665F

P50

Q52915313-4C86AB16-F061-489D-B2A5-1264877E7DE9

P577

Q52915313-CB8D1B87-1620-4208-9BCA-D4EAC2D03963

P698

Q52915313-A6005327-1127-41BC-AAFA-0F0F5C285BD2

P921

Q52915313-4BBD2615-4083-4996-ABAF-17800C21A9F0

Q52915313-54621D84-62EE-40D7-83D7-5FB810928D9B

P356

RCMB.2008-0071OC

P1433

American Journal of Respiratory Cell and Molecular Biology

P1476

Immunostimulation with macroph ...... survival in murine pneumonia.

@en

P2093

Anke Lührmann

http://www.w3.org/2001/XMLSchema#string

Birgitt Gutbier

http://www.w3.org/2001/XMLSchema#string

Hartwig Schütte

http://www.w3.org/2001/XMLSchema#string

Holger C Müller

http://www.w3.org/2001/XMLSchema#string

Karsten Grote

http://www.w3.org/2001/XMLSchema#string

Maren V Zemlin

http://www.w3.org/2001/XMLSchema#string

Martin Witzenrath

http://www.w3.org/2001/XMLSchema#string

Mischo Kursar

http://www.w3.org/2001/XMLSchema#string

Norbert Suttorp

http://www.w3.org/2001/XMLSchema#string

Reinhard Pabst

http://www.w3.org/2001/XMLSchema#string

P2860

Discrimination of bacterial lipoproteins by Toll-like receptor 6

NF-kappaB regulation in the immune system

Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability

Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components

The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling

Recognition of microorganisms and activation of the immune response

Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.

Respiratory viral infection predisposing for bacterial disease: a concise review.

The antineutrophil cytoplasmic antibody-associated vasculitides.

Toll-like receptor 2 deficiency delays pneumococcal phagocytosis and impairs oxidative killing by granulocytes.

P304

474-481

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1165/RCMB.2008-0071OC

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18931326

http://www.w3.org/2001/XMLSchema#string

P921